243 related articles for article (PubMed ID: 14520472)
1. Increased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells.
Smartt HJ; Elder DJ; Hicks DJ; Williams NA; Paraskeva C
Br J Cancer; 2003 Oct; 89(7):1358-65. PubMed ID: 14520472
[TBL] [Abstract][Full Text] [Related]
2. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
3. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
Han S; Inoue H; Flowers LC; Sidell N
Clin Cancer Res; 2003 Oct; 9(12):4627-35. PubMed ID: 14555539
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.
Yao M; Lam EC; Kelly CR; Zhou W; Wolfe MM
Br J Cancer; 2004 Feb; 90(3):712-9. PubMed ID: 14760389
[TBL] [Abstract][Full Text] [Related]
5. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer.
Wong BC; Jiang Xh; Fan XM; Lin MC; Jiang SH; Lam SK; Kung HF
Oncogene; 2003 Feb; 22(8):1189-97. PubMed ID: 12606945
[TBL] [Abstract][Full Text] [Related]
6. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
Elder DJ; Halton DE; Playle LC; Paraskeva C
Int J Cancer; 2002 May; 99(3):323-7. PubMed ID: 11992399
[TBL] [Abstract][Full Text] [Related]
7. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
8. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
9. [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
Zhang YC; Wang S; Zhang H; Ye YJ; Liang B; Cui ZR
Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):583-6. PubMed ID: 15144595
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Shishodia S; Aggarwal BB
Cancer Res; 2004 Jul; 64(14):5004-12. PubMed ID: 15256475
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398.
Elder DJ; Halton DE; Crew TE; Paraskeva C
Int J Cancer; 2000 May; 86(4):553-60. PubMed ID: 10797271
[TBL] [Abstract][Full Text] [Related]
13. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
14. The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF-kappaB activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells.
Moalic-Juge S; Liagre B; Duval R; Corbiere C; Bianchi A; Bordji K; Bosgiraud C; Beneytout JL
Int J Oncol; 2002 Jun; 20(6):1255-62. PubMed ID: 12012007
[TBL] [Abstract][Full Text] [Related]
15. NS-398 induces apoptosis in human esophageal cancer cells through inhibition of NF-kappaB downstream regulation of cyclooxygenase-2.
Liu JF; Zhu GJ; Jamieson GG; Wu TC; Zhu TN; Shan BE; Drew PA
Cancer Invest; 2009 Jan; 27(1):17-23. PubMed ID: 19160097
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
[TBL] [Abstract][Full Text] [Related]
17. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
Ogunwobi OO; Beales IL
Regul Pept; 2006 Mar; 134(1):1-8. PubMed ID: 16169610
[TBL] [Abstract][Full Text] [Related]
18. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells.
Shureiqi I; Chen D; Lotan R; Yang P; Newman RA; Fischer SM; Lippman SM
Cancer Res; 2000 Dec; 60(24):6846-50. PubMed ID: 11156377
[TBL] [Abstract][Full Text] [Related]
19. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Cheng AS; Chan HL; Leung WK; Wong N; Johnson PJ; Sung JJ
Int J Oncol; 2003 Jul; 23(1):113-9. PubMed ID: 12792783
[TBL] [Abstract][Full Text] [Related]
20. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
